Relay Therapeutics Is Maintained at Overweight by Barclays
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $14
We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
Relay Therapeutics Is Maintained at Market Outperform by JMP Securities
Relay Therapeutics Price Target Cut to $21.00/Share From $24.00 by JMP Securities
Express News | JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $21
Market Outperform Rating Maintained for Relay Therapeutics Amidst Promising Developments of RLY-2608
Roche (RHHBY.US) abandons a SHP2 conformational inhibitor.
The partnership agreement was reached on December 14, 2020.
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $18
Maintaining Buy Rating on Relay Therapeutics: Future Catalysts Counterbalance SHP2 Setback
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18
Express News | Relay Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $18 From $20
Express News | Relay Therapeutics: Got Notice of Termination of Collaboration & License Agreement, Dated Dec 11, 2020 With Genentech & F. Hoffmann-La Roche
Barclays Issues a Buy Rating on Relay Therapeutics (RLAY)
Relay Closes $35 Million Series B Funding to Drive Greater Productivity and Safety for Frontline Businesses and Workers
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 29% Of Holding
Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $15 to $28
Relay Therapeutics Analyst Ratings